TNFSF10 and non-small cell lung carcinoma: TRAIL treatment leads to reduced viability in NSCLC cell line H460 at very low concentration (200 ng/ml), but has no significant effect on A549 cells even at very high concentration (1000 ng/ml) (Fig. 1A).